Format
Sort by
Items per page

Send to

Choose Destination

Links from Nucleotide

Items: 1 to 20 of 182

1.

Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions.

Sadras T, Heatley SL, Kok CH, Dang P, Galbraith KM, McClure BJ, Muskovic W, Venn NC, Moore S, Osborn M, Revesz T, Moore AS, Hughes TP, Yeung D, Sutton R, White DL.

Cancer Lett. 2017 Nov 1;408:92-101. doi: 10.1016/j.canlet.2017.08.034. Epub 2017 Sep 1.

PMID:
28866095
2.

Architecture of the human interactome defines protein communities and disease networks.

Huttlin EL, Bruckner RJ, Paulo JA, Cannon JR, Ting L, Baltier K, Colby G, Gebreab F, Gygi MP, Parzen H, Szpyt J, Tam S, Zarraga G, Pontano-Vaites L, Swarup S, White AE, Schweppe DK, Rad R, Erickson BK, Obar RA, Guruharsha KG, Li K, Artavanis-Tsakonas S, Gygi SP, Harper JW.

Nature. 2017 May 25;545(7655):505-509. doi: 10.1038/nature22366. Epub 2017 May 17.

3.

Low MUC4 expression is associated with survival benefit in patients with resectable pancreatic cancer receiving adjuvant gemcitabine.

Urey C, Andersson B, Ansari D, Sasor A, Said-Hilmersson K, Nilsson J, Andersson R.

Scand J Gastroenterol. 2017 May;52(5):595-600. doi: 10.1080/00365521.2017.1290134. Epub 2017 Feb 15.

PMID:
28270046
4.

MUC4, a novel immunohistochemical marker identified by gene expression profiling, differentiates pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma.

Amatya VJ, Kushitani K, Mawas AS, Miyata Y, Okada M, Kishimoto T, Inai K, Takeshima Y.

Mod Pathol. 2017 May;30(5):672-681. doi: 10.1038/modpathol.2016.181. Epub 2017 Jan 27.

5.

NIDO, AMOP and vWD domains of MUC4 play synergic role in MUC4 mediated signaling.

Zhu Y, Zhang JJ, Peng YP, Liu X, Xie KL, Tang J, Jiang KR, Gao WT, Tian L, Zhang K, Xu ZK, Miao Y.

Oncotarget. 2017 Feb 7;8(6):10385-10399. doi: 10.18632/oncotarget.14420.

6.

MiR-211 inhibits invasion and epithelial-to-mesenchymal transition (EMT) of cervical cancer cells via targeting MUC4.

Xu D, Liu S, Zhang L, Song L.

Biochem Biophys Res Commun. 2017 Apr 1;485(2):556-562. doi: 10.1016/j.bbrc.2016.12.020. Epub 2016 Dec 5.

PMID:
27923652
7.

Effects of RNAi-mediated MUC4 gene silencing on the proliferation and migration of human pancreatic carcinoma BxPC-3 cells.

Li Y, Wu C, Chen T, Zhang J, Liu G, Pu Y, Zhu J, Shen C, Zhang Y, Zeng N, Zhang X.

Oncol Rep. 2016 Dec;36(6):3449-3455. doi: 10.3892/or.2016.5152. Epub 2016 Oct 6.

PMID:
27748843
8.

TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.

Mercogliano MF, De Martino M, Venturutti L, Rivas MA, Proietti CJ, Inurrigarro G, Frahm I, Allemand DH, Deza EG, Ares S, Gercovich FG, Guzmán P, Roa JC, Elizalde PV, Schillaci R.

Clin Cancer Res. 2017 Feb 1;23(3):636-648. doi: 10.1158/1078-0432.CCR-16-0970. Epub 2016 Oct 3.

9.

MUC4 impairs the anti-inflammatory effects of corticosteroids in patients with chronic rhinosinusitis with nasal polyps.

Milara J, Morell A, Ballester B, Armengot M, Morcillo E, Cortijo J.

J Allergy Clin Immunol. 2017 Mar;139(3):855-862.e13. doi: 10.1016/j.jaci.2016.06.064. Epub 2016 Sep 14.

PMID:
27639937
10.

Eosinophil peroxidase activates cells by HER2 receptor engagement and β1-integrin clustering with downstream MAPK cell signaling.

Hennigan K, Conroy PJ, Walsh MT, Amin M, O'Kennedy R, Ramasamy P, Gleich GJ, Siddiqui Z, Glynn S, McCabe O, Mooney C, Harvey BJ, Costello RW, McBryan J.

Clin Immunol. 2016 Oct;171:1-11. doi: 10.1016/j.clim.2016.08.009. Epub 2016 Aug 9.

11.

Functional Consequences of Differential O-glycosylation of MUC1, MUC4, and MUC16 (Downstream Effects on Signaling).

Hanson RL, Hollingsworth MA.

Biomolecules. 2016 Jul 30;6(3). pii: E34. doi: 10.3390/biom6030034. Review.

12.

Prognostic Role of Mucin Antigen MUC4 for Cholangiocarcinoma: A Meta-Analysis.

Li B, Tang H, Zhang A, Dong J.

PLoS One. 2016 Jun 15;11(6):e0157878. doi: 10.1371/journal.pone.0157878. eCollection 2016.

13.

The role of the AMOP domain in MUC4/Y-promoted tumour angiogenesis and metastasis in pancreatic cancer.

Tang J, Zhu Y, Xie K, Zhang X, Zhi X, Wang W, Li Z, Zhang Q, Wang L, Wang J, Xu Z.

J Exp Clin Cancer Res. 2016 Jun 10;35(1):91. doi: 10.1186/s13046-016-0369-0. Erratum in: J Exp Clin Cancer Res. 2017 Feb 22;36(1):34.

14.

Aberrant methylation of MUC1 and MUC4 promoters are potential prognostic biomarkers for pancreatic ductal adenocarcinomas.

Yokoyama S, Higashi M, Kitamoto S, Oeldorf M, Knippschild U, Kornmann M, Maemura K, Kurahara H, Wiest E, Hamada T, Kitazono I, Goto Y, Tasaki T, Hiraki T, Hatanaka K, Mataki Y, Taguchi H, Hashimoto S, Batra SK, Tanimoto A, Yonezawa S, Hollingsworth MA.

Oncotarget. 2016 Jul 5;7(27):42553-42565. doi: 10.18632/oncotarget.9924.

15.

Bile acids-mediated overexpression of MUC4 via FAK-dependent c-Jun activation in pancreatic cancer.

Joshi S, Cruz E, Rachagani S, Guha S, Brand RE, Ponnusamy MP, Kumar S, Batra SK.

Mol Oncol. 2016 Aug;10(7):1063-77. doi: 10.1016/j.molonc.2016.04.007. Epub 2016 Apr 29.

16.

Low Expression of Mucin-4 Predicts Poor Prognosis in Patients With Clear-Cell Renal Cell Carcinoma.

Fu H, Liu Y, Xu L, Chang Y, Zhou L, Zhang W, Yang Y, Xu J.

Medicine (Baltimore). 2016 Apr;95(17):e3225. doi: 10.1097/MD.0000000000003225.

17.

Hypoxia-induced oxidative stress promotes MUC4 degradation via autophagy to enhance pancreatic cancer cells survival.

Joshi S, Kumar S, Ponnusamy MP, Batra SK.

Oncogene. 2016 Nov 10;35(45):5882-5892. doi: 10.1038/onc.2016.119. Epub 2016 Apr 25.

18.

Differential Expression of MUC12, MUC16, and MUC20 in Patients with Active and Remission Ulcerative Colitis.

Yamamoto-Furusho JK, Ascaño-Gutiérrez I, Furuzawa-Carballeda J, Fonseca-Camarillo G.

Mediators Inflamm. 2015;2015:659018. doi: 10.1155/2015/659018. Epub 2015 Dec 6.

19.

Transcriptome analysis reveals mucin 4 to be highly associated with periodontitis and identifies pleckstrin as a link to systemic diseases.

Lundmark A, Davanian H, Båge T, Johannsen G, Koro C, Lundeberg J, Yucel-Lindberg T.

Sci Rep. 2015 Dec 21;5:18475. doi: 10.1038/srep18475.

20.

Possible prediction of the response of esophageal squamous cell carcinoma to neoadjuvant chemotherapy based on gene expression profiling.

Shen LY, Wang H, Dong B, Yan WP, Lin Y, Shi Q, Chen KN.

Oncotarget. 2016 Jan 26;7(4):4531-41. doi: 10.18632/oncotarget.6554.

Supplemental Content

Support Center